The Food and Drug Administration on Monday approved Novartis' experimental drug kisqali.
Kisqali is an oral drug that serves as a first-line treatment for post menopausal women with breast cancer when used in combination with letrozole, another type of breast cancer drug.
The drug slows cancer progression by limiting the over-activation of two proteins that can cause cancer cells to grow and divide too quickly, according to a news release.
More articles on supply chain:
Do PBMs disrupt patient-physician relationships? 6 thoughts
Which news channel covers high drug costs the most?
6 things keeping supply chain leaders up at night